Skip to content

UroGen Pharma URGN Operating margin

Discontinued — last reported Q2 '21

Operating margin at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
26.4%+2.8pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-185.4%-83.3pp
CG Oncology logo
CG OncologyCGON
-4,239%-1,872pp
Nuvation Bio logo
Nuvation BioNUVB
-105%-52.0pp
Immunome logo
ImmunomeIMNM
-5,947.9%-12,002pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-83.8%-3.0pp

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.71B+71.7%
Enterprise value$1.8B+80.9%
P/S12.2×+1.3×

Profitability

See full
Gross margin89.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Calculated from UroGen Pharma’s reported figures.

Based on trailing twelve months.

The official record: UroGen Pharma’s 10-Q, filed August 4, 2021, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's operating margin?
UroGen Pharma (URGN) reported operating margin of -329.7% in Q2 2021.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.